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Granulomatosis with polyangiitis (GPA) 
or ANCA associated vasculitis (AAV): 
a case report 
ABSTRACT
GPA is a systemic, necrotizing, small-vessel vasculitis associated with circulating anti-neutrophil cyto-
plasmic autoantibodies (ANCA), and so-called ANCA-associated vasculitis (AAV). A white woman in her 
early thirties was sent to the hospital because of hemoptysis, dyspnea, fever, cough, general fatigue, 
swollen joints. Chest radiography on hospital admission detected diffuse small nodules in both lungs. 
Laboratory tests: white blood cells 13.9…16.7…18.2 × 109/L, hemoglobin 91…80…110g/L, hematocrit 
30…25..35%, erythrocytes 3.7…3.1…4.2 × 1012/L, platelet count 4.45…5.5…5.7 × 109/L, sedimentation 
rate 72…60…45mm/h per the first hour, C-reactive protein 111…80…35mg/L, D-dimer 4100…3500…1250 
ng/ml. Biochemistry analysis: kidney function tests (blood urea nitrogen 10.4…7.4…5.6 mmol/L, creatinine 
110…95…87 μmol/L, liver tests normal, albumin 28g/L, total protein 58 g/l. Urinalysis: mild proteinuria 
(+), 16–18 red blood cells, epithelial cells (++), 24-hour proteinuria 0,52g/L. Gas analyses: partial oxygen 
pressure 7.6…8.9…9.3 kPa, the partial pressure of carbon dioxide 3.7…4.2…4.6 kPa, oxygen saturation 
90…93…95%. She was febrile 38.5°C, heart rate 122 beats/minute, swollen ankles, pale skin, conjunctival 
hyperemia, coagulated blood in both nostrils. Lung auscultation sounds normal. Lung CT scan detected 
diffuse, bilateral, small nodules, some of them with areas of cavitation and pseudo-cavitation. Autoimmune 
antibody tests: positive c-ANCA 95U/ml, negative p-ANCA, negative RF 158IU/ml, positive antiprotein-
ase-3 900 U/ml. Renal ultrasonography normal. IL-6 serum level normal 5 pg/ml, also C3 level 1.2 g/L 
and C4 level 0.3 g/L. Lung ultrasonography: bilateral, irregular, subpleural, hypoechogenic changes, with 
different size and central necrosis. Tracheobronchial mucosa was vulnerable, inflamed and edematous, 
bronchial lavage negative for malignancy and infection. Bronchial biopsy detected necrotic granulomas 
with multinucleated giant and inflammatory cells confirming the diagnosis of PGA. Cyclophosphamide 
combined with corticosteroids was given four months until the time of remission. The corticosteroid dose 
was slowly reduced and cyclophosphamide was switched to azathioprine to maintain remission. The 
treatment duration of the maintenance immunosuppressive medication after 10 months follow up is still 
ongoing with continuous monitoring of side effects. 
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Introduction 
Vasculitides according to the size of vessel involve-
ment are divided in large (giant cell arteritis), medium 
(polyarteritis nodosa) and small-vessel vasculitides 
(ANCA-associated vasculitides, AAV). Granulomatosis 
with polyangiitis (GPA), microscopic polyangiitis and 
eosinophilic granulomatosis with polyangiitis belong 
(EGPA) to AAV [1]. GPA is a systemic, necrotizing, 
small to medium-sized blood vessels, characterized by 
granulomatous inflammation, pauci-immune necrotizing 
glomerulonephritis, vasculitis, and an association with 
circulating anti-neutrophil cytoplasmic autoantibodies 
(ANCA), and is so-called AAV. Estimates of the overall 
incidence range between 0.5–20 cases/million with 
a prevalence of 20–160 cases/million,  dominantly in 
middle Europe and Australia/New Zealand, and rela-
tively rare in non-Caucasian populations [2]. AAV is 
a chronic disease, and greater emphasis has turned to 
improving treatment-related toxicity, reducing relapses 
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and providing alternative treatments for refractory dis-
ease. Since the introduction of cyclophosphamide and 
high-dose glucocorticoids in the 1970s, AAV has trans-
formed from a disease with 80% mortality, into chronic 
relapsing and remitting disease with 10–20% 1-year 
mortality. Current outcomes at 5 years are 25% mortality 
and a 50% relapse rate [3]. Nowadays, remission can 
be achieved and maintained in most cases with a com-
bination of high-dose steroid and immunosuppressive 
drugs (methotrexate, azathioprine, cyclophosphamide, 
rituximab, tocilizumab, mofetil mycophenolate) [1, 4–5]. 
This therapy has to be continued for at least 24 months 
(3–6 months of remission induction therapy, followed by 
12–24 months of remission maintenance therapy) after 
a substantial remission has been obtained because 
the early cessation of treatment is associated with 
an increased risk of relapse. For this reason, patients 
should be regularly monitored in order to promptly 
diagnose and treat a possible recurrence of AAV [3, 
6]. Targeted immunotherapy is substantially improving 
the management of AAV [7]. Rituximab, an anti-CD20 B 
cell-depleting therapy, has been used for over a decade 
in patients with AAV, offers a significant advance in the 
treatment of these diseases. It has an established role 
for remission induction and is now being investigated as 
a remission maintenance agent. In patients at risk of ma-
lignancy, women of childbearing potential, and patients 
previously treated with cyclophosphamide, rituximab 
may be considered preferable to cyclophosphamide, 
which has well-established malignancy risks. Also is 
more effective than cyclophosphamide for treating 
relapses. [3, 6]. Treatment with tocilizumab was able 
to induce a complete and sustained disease remission 
in a patient with severe multisystemic MPA, as well as 
normalization of circulating levels of IL-6-associated 
pro-inflammatory cytokines and chemokines [5].  Main-
tenance treatment with the interleukin-5 antagonist, 
mepolizumab is effective in decreasing glucocorticoid 
requirements and in alleviating asthma and sinona-
sal symptoms, its efficacy on the vasculitis remains 
somewhat unclear. Omalizumab as a recombinant, 
humanized, a monoclonal antibody against human 
immunoglobulin E have been reported to be efficacious 
in refractory asthma associated with EGPA. Belimumab, 
an anti-B lymphocyte stimulatory monoclonal antibody 
is in clinical trials for the management of GPA [7–9]. Im-
munoglobulins can be helpful as an adjuvant treatment 
for active AAV with severe immune depression, notably 
when infections occur. Plasma exchange is indicated 
in AAV with advanced renal dysfunction and, perhaps, 
in the event of alveolar hemorrhage. Plasmapheresis 
is effective for very severe disease, reducing dialysis 
dependence from 60 to 40% in the first year, but with no 
effect on mortality or long-term renal function, probably 
due to established renal damage [7, 10]. Structured 
clinical assessment using the Birmingham Vasculitis 
Activity Score and Vasculitis Damage Index should form 
the basis of an individual treatment plan and personalize 
the care of AAV patients [10]. 
Case presentation
A white woman in her early thirties was sent to our 
hospital because of hemoptysis, shortness of breath, 
fever, cough, general fatigue, swollen joints. She 
claimed to be healthy until a few months ago when 
epistaxis and fever appeared. Laboratory and chest 
radiograph were normal in that period. Because of 
symptom progression, another chest radiography was 
performed and massive right paracardial consolida-
tion was noted (Fig. 1). Routine blood work revealed: 
white blood cells 13.9…16.7…18.2 × 109/L, hemo-
globin 91…80…110g/L, hematocrit 30…25..35%, 
erythrocytes 3.7…3.1…4.2 × 1012/L, platelet count 
4.45…5.5…5.7×109/L, sedimentation rate (ESR) was 
elevated 72…60…45mm/h per the first hour (ref. 
values 0-20 mm per hour), C-reactive protein (CRP) 
111…80…35mg/L (ref. range less than 3.03 mg/L), D-di-
mer 4100…3500…1250 ng/ml (ref range < 500 ng/ml). 
Biochemistry analysis: kidney function tests (blood 
urea nitrogen 10.4…7.4…5.6 mmol/ (normal values 
2.8–7.2 mmol/L), creatinine 110…95…87 μmol/L (ref. 
range 49–115 μmol/L), liver function tests normal, 
albumin 28g/L (ref range 34–50 g/L), total protein 
Figure 1. Chest X-ray showing right paracardial consolidation




Figure 2. A, B — Lung CT scan presenting diffuse, bilateral, nodules in lung parenchyma; C — large lung infiltrate with 
central necrosis in right lower lobe
58 g/l (normal range 66–83 g/L). Urinalysis showed 
mild proteinuria (+) with a few red blood cell 16–18, 
epithelial cells (++). Twenty-four-hour urinary protein 
collection revealed mild proteinuria 0,52g/L (upper 
limit 0,2g/L). Gas analyses revealed hypoxemia at the 
beginning 7.6…8.9…9.3 kPa, hypocapnia at admission 
3.7…4.2…4.6 kPa, oxygen saturation 90…93…95%. 
Physical examination on admission, blood pressure 
120/70mmHg, body temperature 38.5°C, heart rate 
122 beats/minute. Swollen ankles, pale skin, conjuncti-
val hyperemia, coagulated blood in both nostrils. Lung 
auscultation sounds normal, heart rate rhythmic, 
tachycardic, no murmurs. Abdominal examination 
without pathological findings. According to anamnesis: 
cigarette smoker, mother of one child, no allergies 
reported, no chronic therapy. ECG with sinus tachy-
cardia of 122 beats/min, axis normal, no signs of acute 
heart injury. Lung computed tomography scan (CT) 
detected diffuse, bilateral, small nodules, some of them 
with areas of cavitation and pseudo-cavitation and 
no evidence of thrombosis on CT angiography pro-
tocol (Fig. 2). Rheumatologist and nephrologist were 
consulted and tests for autoimmune disease showed 
positive c-ANCA 95U/ml (normal up to 30U/ml), neg-
ative p-ANCA, RF 158IU/ml, antiproteinase 3 value 
900 (ref. < 20) (findings suggesting the diagnosis of 
GPA), kidney function tests and renal ultrasonography 
normal. IL-6 serum level was normal 5 pg/ml (ref range 
2–5.9 pg/ml), C3 level 1.2 g/L (ref range 0.9–1.8 g/L) 
and C4 level 0.3 g/L (ref range 0.1–0.4 g/L). Lung ul-
trasonography detected bilateral, irregular, subpleural, 
hypoechogenic changes, with central necrosis (Fig. 3). 
Figure 3. Chest ultrasonography presenting multiple subpleural, hypoechogenic changes with central necrosis
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A B C
Figure 4. A — Video bronchoscope image presenting edematous, vulnerable respiratory mucosa leading to stenosis of 
the right intermediate bronchus; B — Video bronchoscope image presenting bleeding of bronchial inflamed mucosa); 
C — Video bronchoscope image presenting complete resolution of inflamed bronchial mucosa of the right lower lobe)
Echocardiography did not detect pericardial effusion. 
Mantoux test was negative. Bronchoscopy finding of 
coagulated blood in both nostrils was the reason for 
oral intubation. Tracheobronchial mucosa was vulner-
able, inflamed and edematous (Fig. 4 A–B). Cytology 
report of bronchial alveolar lavage (BAL) reported 
elevated neutrophils. Bronchial lavage was negative 
for malignancy and infection (microbiology cultivation 
of BAL specimen and Gene X-pert were negative). 
Biopsy detected necrotic granulomas with multinu-
cleated giant and inflammatory cells confirming the 
diagnosis of PGA. The treatment was multidisciplinary 
and consisted of antipyretic, fluids, wide-spectrum an-
tibiotic, low molecular weight heparin, fluids, vitamins, 
oxygen, systemic steroids (pulse methylprednisolone 
followed by oral prednisone prednisolone gradually 
decreasing the dose) and intravenous cyclophos-
phamide (Cytoxan) as remission induction therapy. 
Cyclophosphamide combined with corticosteroids 
was given four months until the time of remission. 
There was significant symptom relief, improvement 
in joint pain and hemoptysis subsided (Fig 4 C). The 
corticosteroid dose was slowly reduced and cyclo-
phosphamide was switched to azathioprine (Imuran) 
to maintain remission. The treatment duration of the 
maintenance immunosuppressive medication  after 
10 months follow-up is still ongoing with continuous 
monitoring of side effects. 
Discussion
ANCAs are typically classified as either myeloper-
oxidase (MPO)-ANCA, proteinase 3 (PR3)-ANCA and 
atypical-ANCA. The clinical significance of the two 
common types or ANCA subsets, MPO-ANCA and 
PR3-ANCA, differs. MPO-ANCA is often associated with 
microscopic polyarteritis, necrotizing glomerulonephri-
tis and Churg-Strauss syndrome, whereas PR3-ANCA 
is found primarily in patients exhibiting PGA [11]. There 
are various infections that have been known to lead to 
secondary elevation of serum ANCA (tuberculosis, in-
fective endocarditis, hepatitis B), also other autoimmune 
disorders (rheumatoid arthritis, inflammatory bowel 
disease, cystic fibrosis, systemic lupus erythematosus, 
primary sclerosing cholangitis), cancer [11, 12]. Various 
factors may have an impact on the etiology of GPA 
which is treated as an autoimmune disease. Genetic 
factors, infectious agents (like Staphylococcus aureus), 
environmental factors (like silica, hydrocarbons, fumes, 
pesticides, and farming) are considered elements for 
the development of the disease. Mostly, GPA affects 
the upper and lower respiratory tracts and kidneys 
and associated with otorhinolaryngological and renal 
manifestations. However, numerous untypical manifes-
tations may also occur [13]. The American College of 
Rheumatology established the following classification 
criteria for GPA: (1) abnormal urinary sediment, [2] 
abnormal findings on chest radiograph, [3] oral ulcers 
or nasal discharge, and [4] granulomatous inflamma-
tion on biopsy [14]. Here, we have described a case 
of GPA dominantly presented with lung manifestations 
(hemoptysis and alveolar hemorrhage). Bronchoscopy 
as an essential diagnostic in procedure in the evaluation 
of alveolar hemorrhage, infection, airway disease, and 
endobronchial lesions, leads to the diagnosis of PGA 
in our patient. Involvement of the respiratory mucosa 
can occur along the entire length of the lower and 
upper airways in 15-55% of the patients with GPA. In 
25% of the patients with GPA, the involvement of the 
airways can be the only manifestation [15]. Levels of 
C3 and C4 were normal, hypocomplementemia with low 
C3 and/or C4 levels at GPA or MPA diagnosis may be 
responsible for worse survival and renal prognosis [16]. 
Platelet to lymphocyte ratio (PLR) as a useful index to 
estimate the current activity of vasculitis in AAV patients, 
Daniela Buklioska Ilievska, Granulomatosis with polyangiitis or ANCA associated vasculitis
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in our patient was 115, the value > 160 is associated 
with poor prognosis [17]. 
Conclusion
GPA is a huge challenge for contemporary di-
agnostics and medicine. High-dose corticosteroids 
along with other immunosuppressants like cyclo-
phosphamide resulted in significant resolution in our 
case. Newer therapies are being investigated in order 
to further improve disease-related outcomes, reducing 
refractory disease, relapse, chronic organ damage and 
reduced toxicity.
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